Progyny Intrinsic Value Calculation – PROGYNY Reports Third Quarter FY2023 Earnings Results on September 30, 2023
November 21, 2023
🌥️Earnings Overview
On September 30 2023, PROGYNY ($NASDAQ:PGNY) announced their financial results for the third quarter of the 2023 fiscal year, which concluded on the same day. Total revenue for the quarter was USD 280.9 million, representing an increase of 36.8% year over year. Net income was reported at USD 15.9 million, an increase of 20.4% from the same quarter in the prior year.
Market Price
PROGYNY opened at $31.0 and closed at $32.0, representing a 3.8% increase from its previous closing price of $30.8. Investors reacted positively to the earnings results, as the stock saw a surge in activity with over 11 million shares traded throughout the day. This was mainly driven by growth in their core business and significant new customer wins. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Progyny. More…
| Total Revenues | Net Income | Net Margin |
| 1.03k | 51.98 | 5.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Progyny. More…
| Operations | Investing | Financing |
| 202.67 | -108.28 | -8.83 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Progyny. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 726.51 | 211.12 | 5.38 |
Key Ratios Snapshot
Some of the financial key ratios for Progyny are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 49.4% | 82.2% | 5.0% |
| FCF Margin | ROE | ROA |
| 19.3% | 6.6% | 4.4% |
Analysis – Progyny Intrinsic Value Calculation
GoodWhale recently conducted an analysis on PROGYNY‘s fundamentals and are pleased to present the results. According to our proprietary Valuation Line, the intrinsic value of a PROGYNY share is around $71.6. This means that the stock is currently trading at $32.0, resulting in a 55.3% undervaluation. We believe that this presents a great opportunity for investors to gain exposure to PROGYNY at a discounted rate. More…
Peers
Its competitors are Owlet Inc, ATI Physical Therapy Inc, NantHealth Inc.
– Owlet Inc ($NYSE:OWLT)
Owlet Inc is a privately held company that provides smart baby monitoring products and services. The company was founded in 2013 and is headquartered in Lehi, Utah. Owlet’s product line includes the Owlet Smart Sock, a wearable sensor that monitors a baby’s heart rate and oxygen levels; the Owlet Cam, a Wi-Fi connected camera that streams live video and audio to a smartphone; and the Owlet App, which allows parents to track their baby’s health data. Owlet has raised over $50 million in venture capital funding, and its products are available for purchase online and in select retail stores.
– ATI Physical Therapy Inc ($NYSE:ATIP)
ATI Physical Therapy Inc is a provider of physical therapy and rehabilitation services in the United States. The company operates through a network of over 300 physical therapy clinics in 27 states. ATI Physical Therapy Inc offers a variety of services, including physical therapy, occupational therapy, and speech-language pathology. The company also provides a range of rehabilitation services, such as sports medicine, workers’ compensation, and concussion management.
– NantHealth Inc ($NASDAQ:NH)
NantHealth Inc is a healthcare technology company that provides solutions to improve clinical outcomes and patient experience. The company has a market cap of $37.84 million and a return on equity of 14.38%. NantHealth’s solutions are used by healthcare providers to manage and coordinate care for patients. The company’s products and services include electronic health records, clinical decision support, and patient engagement.
Summary
ProGYNY Inc. saw a significant increase in revenue and income in the third quarter of FY2023, when compared to the same quarter in the previous year. Total revenue for the quarter was USD 280.9 million, representing a 36.8% increase, while net income increased by 20.4% to USD 15.9 million. This impressive financial performance was highly reflected in the stock price, which rose on the same day. Investors view ProGYNY as an attractive stock investment given its sustainable growth and potential for future expansion.
Related Posts
Recent Posts
